GENOME ANNOUNCEMENT {#h0.0}
===================

Haemophilus influenzae colonizes the human nasopharyngeal mucosa and has the ability to cause a variety of infections, ranging from respiratory to invasive diseases. After the widespread use of the H. influenzae type b (Hib) conjugate vaccines, most invasive H. influenzae infections are nowadays caused by nonencapsulated (ncHi) strains ([@B1][@B2][@B3]). Despite the well-known genetic heterogeneity of the ncHi population ([@B4]), we recently identified a group of closely related clones belonging to multilocus sequence type 103 (ST103), ST139, and ST145 and representing almost 25% of all invasive ncHi strains circulating in Italy ([@B5]). In this study, we determined the whole-genome sequences of 11 ncHi strains ([Table 1](#tab1){ref-type="table"}). Of these, 7 strains belonged to the above-mentioned major clones (6 from invasive disease and 1 from a healthy carrier) and 4 strains (2 from invasive disease and 2 from healthy carriers) were included into uncommon STs (ST34 and ST105).

###### 

Summary of genome sequencing for the 11 H. influenzae isolates in the present study

  Isolate   Source                                       BioSample no.   ST*[^a^](#ngtab1.1){ref-type="table-fn"}*   Accession no.                  Genome coverage (×)   Genome size (Mb)   No. of contigs   No. of genes
  --------- -------------------------------------------- --------------- ------------------------------------------- ------------------------------ --------------------- ------------------ ---------------- --------------
  MiHi64    Nasopharyngeal carriage                      SAMN03284980    34                                          [JXMG00000000](JXMG00000000)   53                    1.98               109              1,986
  Hi345     Blood                                        SAMN03284972    34                                          [JXLY00000000](JXLY00000000)   71                    1.81               22               1,776
  Hi359     Blood                                        SAMN03284973    103                                         [JXLZ00000000](JXLZ00000000)   60                    1.86               30               1,847
  Hi378     CSF*[^b^](#ngtab1.2){ref-type="table-fn"}*   SAMN03284975    103                                         [JXMB00000000](JXMB00000000)   48                    1.92               26               1,909
  RMHi93    Oropharyngeal carriage                       SAMN03284981    105                                         [JXMH00000000](JXMH00000000)   47                    1.94               35               1,938
  Hi322     CSF                                          SAMN03284971    105                                         [JXLX00000000](JXLX00000000)   83                    1.91               33               1,925
  MiHi270   Nasopharyngeal carriage                      SAMN03284979    139                                         [JXMF00000000](JXMF00000000)   60                    1.84               26               1,812
  Hi361     Blood                                        SAMN03284974    139                                         [JXMA00000000](JXMA00000000)   50                    1.84               21               1,805
  Hi381     CSF                                          SAMN03284976    139                                         [JXMC00000000](JXMC00000000)   50                    1.84               24               1,808
  Hi394     Blood                                        SAMN03284977    145                                         [JXMD00000000](JXMD00000000)   58                    1.90               31               1,898
  Hi403     CSF                                          SAMN03284978    145                                         [JXME00000000](JXME00000000)   69                    1.87               31               1,863

ST, sequence type.

CSF, cerebrospinal fluid.

The genomic DNAs were sequenced using Illumina MiSeq (100-bp paired-end reads) technology (Illumina, San Diego, CA). The genome sequences were assembled *de novo* using Celera Assembler7 ([@B6]). The resulting coverage ranged from 47× to 83×, with an average of 59×. Genome annotation was performed using Glimmer3 ([@B7]) and RATT ([@B8]).

The results of genome sequencing are summarized in [Table 1](#tab1){ref-type="table"}. Overall, the ncHi genomes consist of only chromosomal DNA, without any plasmids, with an average length of 1.88 Mb and 1,870 putative protein-coding genes.

In-depth characterization of the reported genomes, including comparative analysis with other publicly available H. influenzae genomes, is under way. The herein-announced 11 genome sequences will help our understanding of the different pathogenic potentials of ncHi invasive isolates, contributing to the identification of relevant molecular and virulence markers possibly associated with the major clones.

Nucleotide sequence accession numbers. {#s1}
--------------------------------------

The genome sequences of the 11 ncHi isolates have been deposited in GenBank with the accession numbers [JXLX00000000](JXLX00000000) to [JXLZ00000000](JXLZ00000000) and [JXMA00000000](JXMA00000000) to [JXMH00000000](JXMH00000000). The versions described in this paper are the first versions, JXLX01000000 to JXLZ01000000 and JXMA01000000 to JXMH01000000, respectively.
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